A phase Ib study of the combination of the aurora kinase inhibitor alisertib (MLN8237) and bortezomib in relapsed multiple myeloma

British Journal of Haematology

Volumn 174, Issue 2, 2016, Pages 323-325

  Rosenthal, Allison ^a   Kumar, Shaji ^b   Hofmeister, Craig ^c   Laubach, Jacob ^d   Vij, Ravi ^e   Dueck, Amylou ^a   Gano, Katherine ^a   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

Alisertib; Aurora kinase; Bortezomib; Multiple myeloma; Relapse

Indexed keywords

ALISERTIB; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CREATININE;

ADULT; ALOPECIA; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; HUMAN; INFECTION; INFESTATION; LETTER; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUTROPHIL COUNT; ORAL MUCOSITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 84978077033     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13765     Document Type: Letter

References (8)

1. Carvajal, R.D., Tse, A. & Schwartz, G.K. (2006) Aurora kinases: new targets for cancer therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12, 6869–6875.
2. Cervantes, A., Elez, E., Roda, D., Ecsedy, J., Macarulla, T., Venkatakrishnan, K., Roselló, S., Andreu, J., Jung, J., Sanchis-Garcia, J.M., Piera, A., Blasco, I., Maños, L., Pérez-Fidalgo, J.-A., Fingert, H., Baselga, J. & Tabernero, J. (2012) Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clinical Cancer Research, 18, 4764–4774.
3. Dees, E.C., Cohen, R.B., von Mehren, M., Stinchcombe, T.E., Liu, H., Venkatakrishnan, K., Manfredi, M., Fingert, H., Burris, H.A. & Infante, J.R. (2012) Phase I study of aurora a kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clinical Cancer Research, 18, 4775–4784.
4. Durie, B.G.M., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467–1473.
5. Falchook, G., Kurzrock, R., Gouw, L., Hong, D., McGregor, K., Zhou, X., Shi, H., Fingert, H. & Sharma, S. (2014) Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Investigational New Drugs, 32, 1181–1187.
6. Kelly, K., Shea, T., Goy, A., Berdeja, J., Reeder, C., McDonagh, K., Zhou, X., Danaee, H., Liu, H., Ecsedy, J., Niu, H., Benaim, E. & Padmanabhan Iyer, S. (2014) Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investigational New Drugs, 32, 489–499.
7. Tiedemann, R.E., Zhu, Y.X., Schmidt, J., Shi, C.X., Sereduk, C., Yin, H., Mousses, S. & Stewart, A.K. (2012) Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Research, 72, 757–768.
8. Zhu, Y.X., Tiedemann, R., Shi, C.-X., Yin, H., Schmidt, J.E., Bruins, L.A., Keats, J.J., Braggio, E., Sereduk, C., Mousses, S. & Stewart, A.K. (2011) RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood, 117, 3847–3857.